Compounds > 1-4-(3-methyltriazeno)benzoic acid
Page last updated: 2024-12-08
1-4-(3-methyltriazeno)benzoic acid
Description
1-4-(3-methyltriazeno)benzoic acid is a chemical compound with the formula **C8H9N3O2**. It is also known as **MTB** or **3-methyl-1-(4-carboxyphenyl)triazene**.
**Why is it important for research?**
MTB has been investigated for its potential as an **anticancer agent**. Its mechanism of action involves the release of a **cytotoxic methylating agent** within tumor cells. This methylation process can disrupt crucial cellular processes, leading to cell death.
Here's a breakdown of its importance:
* **Anti-tumor activity:** MTB has shown promising activity against various cancer cell lines, including those derived from leukemia, lymphoma, and breast cancer.
* **Mechanism of action:** Understanding how MTB works provides valuable insights for developing new and more effective cancer therapies.
* **Potential drug development:** MTB itself may serve as a lead compound for the development of new anticancer drugs, either through modifications to its structure or by using it as a template to design new agents.
However, it's crucial to note that:
* **MTB is not currently approved for clinical use.**
* **Research is ongoing to assess its safety and efficacy in humans.**
* **Further research is needed to determine its therapeutic potential and optimize its use.**
Therefore, while MTB shows promise as a potential anticancer agent, more research is needed to understand its full potential and to develop safe and effective treatment strategies.
1-4-(3-methyltriazeno)benzoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 154190 |
SCHEMBL ID | 22692231 |
MeSH ID | M0152217 |
Synonyms (9)
Synonym |
mtba |
40843-84-3 |
1-4-(3-methyltriazeno)benzoic acid |
1-p-(3-methyltriazeno)benzoic acid potassium salt |
mm-cook |
4-(3-methyl-1-triazenyl)benzoic acid |
benzoic acid, 4-(3-methyl-1-triazenyl)- |
DTXSID20193822 |
SCHEMBL22692231 |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 4 (33.33) | 18.7374 |
1990's | 7 (58.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.80 (24.57) | Research Supply Index | 2.77 (2.92) | Research Growth Index | 4.58 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 1 (7.14%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (92.86%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |